CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
1650-G Vaccinedrug
Likely dose
1650-G Vaccine 6mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00654030
NCT00654030Phase 2Completed
CompareCT.gov

Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC)

Edward Hirschowitz·interventional·Posted Apr 7, 2008·Updated Apr 9, 2018

In Brief

A Phase 2 clinical trial evaluating 1650-G Vaccine for Non-Small Cell Lung Cancer. Completed, enrolled 12 participants across 4 sites.

Detailed Summary

Rationale: Vaccines made from allogeneic tumor cells may help the body build an effective immune response to kill tumor cells. The Purpose of this study is to evaluate the effects of a lung cancer vaccine in patients with Stage I or Stage II Non-Small Cell Lung Cancer (NSCLC) after completion of initial definitive therapies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesUnited States
CollaboratorsKentucky Lung Cancer Research Program

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 7, 2008
Enrollment StartOct 1, 2006
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 18.2 years ago

Interventions

1650-G Vaccinedrug

.6ml injection administered intradermally in the thigh at week 0 and week 4